BIIB.O
Latest Trade
233.79USDChange
-4.91(-2.06%)Volume
585,828Today's Range
-
239.5252 Week Range
-
358.41As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 238.70 |
|---|---|
Open | 239.36 |
Volume | 585,828 |
3M AVG Volume | 30.23 |
Today's High | 239.52 |
Today's Low | 233.72 |
52 Week High | 358.41 |
52 Week Low | 215.78 |
Shares Out (MIL) | 184.45 |
Market Cap (MIL) | 44,027.55 |
Forward P/E | 7.33 |
Dividend (Yield %) | -- |
Biogen Advances Spinal Muscular Atrophy Clinical Research
Samsung Bioepis Announced Expansion Into Brazilian Biopharmaceutical Market
Biogen Says Diroximel Fumarate Demonstrated Improved Gastrointestinal Tolerability Profile Compared To Dimethyl Fumarate In Patients With Multiple Sclerosis
Biogen Inc. is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA). It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions, GAZYVA indicated for the treatment of CLL and follicular lymphoma, and other anti-CD20 therapies. The Company's product candidate includes OCREVUS; Biosimilar adalimumab; Aducanumab; E2609; BIIB074; BAN2401; Opicinumab; CIRARA; BIIB061; BIIB054; BIIB067, and BIIB068.
Industry
Biotechnology & Drugs
Executive Leadership
Stelios B. Papadopoulos
Independent Chairman of the Board
Michel Vounatsos
Chief Executive Officer, Director
Jeffrey D. Capello
Chief Financial Officer, Executive Vice President
Ginger Gregory
Chief Human Resource Officer, Executive Vice President
Susan H. Alexander
Executive Vice President, Chief Legal Officer and Secretary
Price To Earnings (TTM) | 8.84 |
|---|---|
Price To Sales (TTM) | 3.13 |
Price To Book (MRQ) | 3.41 |
Price To Cash Flow (TTM) | 6.99 |
Total Debt To Equity (MRQ) | 45.92 |
LT Debt To Equity (MRQ) | 45.92 |
Return on Investment (TTM) | 24.42 |
Return on Equity (TTM) | 21.33 |
Biogen Inc and Eisai Co Ltd are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.
Biogen Inc and partner Eisai Co Ltd said on Friday they would abandon two late-stage trials testing their experimental treatment, elenbecestat, for patients with early Alzheimer's disease.
Biogen Inc reported better-than-expected second quarter profit and raised its 2019 earnings forecast on Tuesday, driven by higher sales of its top-selling multiple sclerosis drug Tecfidera and lower taxes.
Drugmaker Biogen Inc reported a 72.4% rise in second-quarter profit on Tuesday, boosted by higher sales of its multiple sclerosis treatment Tecfidera and lower research and development costs.
England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.
England's National Health Service said it had reached a deal to pay for U.S. drugmaker Biogen Inc's expensive spinal muscle atrophy treatment Spinraza.
AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.
AbbVie Inc's Chief Executive Officer Richard Gonzalez said on a conference call that rivals Biogen Inc and Amgen Inc had been the most aggressive in Europe with their biosimilar versions of its blockbuster drug Humira.
Biogen Inc on Wednesday beat Wall Street estimates for quarterly profit, but failed to ease investor concerns about long-term growth after it recently shelved the development of an Alzheimer's drug that was expected to be its next blockbuster, sending its shares down 2 percent...
Drugmaker Biogen Inc reported a 20 percent rise in first-quarter profit on Wednesday on higher sales of its muscle disease treatment Spinraza.
Biogen Inc should slash the price of its spinal muscular atrophy (SMA) drug, and the $4 million to $5 million Novartis has said its experimental gene therapy for the disease is worth is excessive, an independent U.S. organization that reviews the value of medical treatments...
Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.
Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.
Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value...
* Analysts question Biogen growth prospects (Recasts first paragraph, adds details; updates shares)
* Analysts question Biogen's growth prospects (Adds context, details, background)
Biogen Inc and Eisai Co Ltd said on Thursday they will discontinue two late-stage trials testing an experimental treatment for Alzheimer's disease.
Japan's Fujifilm Holdings Corp will buy a drugmaking business from U.S.-based Biogen Inc for about $890 million to try to bolster its healthcare business as growth at its legacy photocopy operations stagnates.
Fujifilm Holdings Corp said on Tuesday it is buying a subsidiary of Biogen Inc , Biogen Denmark Manufacturing ApS, for around $890 million to bolster its healthcare business.
Biogen Inc said on Monday it will buy Nightstar Therapeutics Plc for about $800 million in cash as the company looks to tap into a potentially lucrative gene therapy market.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.